---
title: "Tango combo with Revolution’s Rasonque yields 82% response in advanced pancreatic cancer trial"
id: "stat-news-1-stat-tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss"
published_at: "2026-10-23T10:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Tango combo with Revolution’s Rasonque yields 82% response in advanced pancreatic cancer trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss)
- **Published At:** 2026-10-23T10:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported an **82% tumor response rate** with a combination of Tango Therapeutics’ experimental agent and Revolution Medicines’ **Rasonque** in patients with advanced **pancreatic cancer**. - The cohort showed durable control by one measure: **88% of patients were alive without tumor progression at nine months**, according to the report. - The regimen did not include chemotherapy; the study team observed that the data support the concept that combining targeted therapies can benefit pancreatic cancer patients more than single agents. - The article was presented at ESMO and reported from a meeting setting; STAT News labeled the detailed write-up as subscriber-only content. - The source did not report key trial design details in the publicly available excerpt — specifics such as sample size, randomization, eligibility criteria, dosing schedules, comparator arms, statistical endpoints, and adverse-event data were not provided. - Investigators and the reporting author framed the results as encouraging for combination targeted therapy approaches but did not provide regulatory next steps or confirmatory-phase plans in the accessible text. - The study team observed high short-term progression-free survival by the nine-month landmark, but longer-term outcomes and safety signals remain undocumented in the available excerpt. - Data indicated this chemo-free approach may alter treatment thinking for an aggressive malignancy long treated with cytotoxic therapy, yet unanswered clinical questions remain about reproducibility and broader applicability.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss) [rare diseases](https://www.statnews.com/topic/rare-diseases/) [genetics](https://www.statnews.com/topic/genetics/) [neurology](https://www.statnews.com/topic/neurology/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer ## Study presented at ESMO boosts idea that patients benefit more from combining targeted drugs * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Oct. 23, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of [Adam’s Biotech Scorecard](https://www.statnews.com/category/adams-biotech-scorecard/), a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. MADRID — The combination of an experimental drug from Tango Therapeutics and Revolution Medicines’ Rasonque led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed. The responses were also durable: 88% of the patients were still alive without tumor progression when assessed at nine months. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2026/09/Solano-Family-768x432.jpg) ### [A breakthrough pancreatic cancer drug won approval. They still struggle to access it](https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/) The new data bolster the theory that patients with pancreatic cancer can derive more benefit from combinations of targeted drugs than single drugs. The Tango regimen is also notable for the absence of chemotherapy, long considered a standard treatment for the aggressive cancer. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Cancer](https://www.statnews.com/topic/cancer/), [drug development](https://www.statnews.com/topic/drug-development/), [ESMO](https://www.statnews.com/topic/esmo/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/Andrea-Carol-Miranda-in-Medford-1990-80x80.jpg) [The inherited disease my family called ‘it’ had a name, which changed everything](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AP25119697127797-80x80.jpg) [Overdose deaths have plunged. We need to know why](https://www.statnews.com/2026/10/23/opioid-deaths-fallen-naloxone-treatment-supply-shock-public-health/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2299832720-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [State officials scrambling to implement Medicaid work requirements meet up to swap notes](https://www.statnews.com/2026/10/23/state-medicaid-officials-prepare-for-new-work-requirements/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/07/GLP1-48-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2208174977-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In DOGE’s aftermath, federal health workers bristle at new performance reviews](https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/4LK3WINEDMMIR2JEHVX56ICPOY-80x80.avif) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Jury rules in favor of ousted Cambridge scientist David Sabatini, with $6 million in damages to be awarded](https://www.statnews.com/2026/10/16/david-sabatini-wins-sexual-misconduct-lawsuit-metoo/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/07/GLP1-48-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam says Huntington’s drug shows promise in early study ](https://www.statnews.com/2026/10/23/huntingtons-alnylam-gene-silencing-brezosiran/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) and [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial ](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) and [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations ](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/) By [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Will the Treasury restrict U.S. investment in the Chinese biotech sector? ](https://www.statnews.com/2026/10/22/biotech-news-treasury-restrictions-for-us-investment-in-chinese-biotech/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) and [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to expect from the Moderna-Merck cancer vaccine data reveal ](https://www.statnews.com/2026/10/22/esmo-2026-what-to-know-ahead-of-moderna-merck-c
## Related Clinical Research

- [Daraxonrasib for pancreatic cancer: one family’s account of benefit and barriers](https://medichelpline.com/clinical-feed/stat-news-5-one-family-s-story-of-a-life-extending-medicine-for-pancreatic-cancer.md)
- [Targeted Crizotinib Therapy Extends Survival in ROS1 Lung Cancer Patient](https://medichelpline.com/clinical-feed/stat-news-4-how-a-targeted-drug-kept-one-patient-alive-15-years-but-failed-to-save-her.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [High-Fiber Diet Outperforms Metformin in Blood Sugar Control and Weight Loss](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fiber-diet-vs-metformin-which-is-better-for-blood-sugar-control-weight-loss.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.